Skip to search formSkip to main contentSkip to account menu

valbenazine

National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

NBI-98854

Broader (2)

TetrabenazineValine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
T8. NEUROLOGICAL SOFT SIGNS (NSS) IN SCHIZOPHRENIA: AN UPDATE ON THE STATE- VERSUS TRAIT-PERSPECTIVE
Abstract Background Neurological soft signs (NSS) represent minor neurological signs which indicate non-specific cerebral… 
Review
2018
Review
2018
Deuterium Tetrabenazine for Tardive Dyskinesia.
Tardive dyskinesia remains a significant, potentially stigmatizing or crippling adverse effect for any patient treated with an… 
Review
2018
Review
2018
Reprint of: Clinical management of tardive dyskinesia: Five steps to success
2018
2018
Effectiveness and Value of 2 Novel Treatments for Tardive Dyskinesia
2017
2017
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
BACKGROUND Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment… 
2017
2017
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
BACKGROUND The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind… 
2017
2017
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
BACKGROUND Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment… 
Review
2017
Review
2017
Valbenazine for the treatment of tardive dyskinesia
ABSTRACT Introduction: Tardive dyskinesia (TD) is a hyperkinetic movement disorder that may result from treatment with… 
2017
2017
Successful Treatment of Severe Tardive Dyskinesia with Valbenazine, Including a Patient’s Perspective
Patient: Female, 49 Final Diagnosis: Tardive dyskinesia Symptoms: Dyskinesia • dystonia Medication: — Clinical Procedure: Oral… 
2016
2016
Open-Label Extension of KINECT: A Phase 2 Study of Valbenazine (NBI-98854) for Tardive Dyskinesia (S27.001)
Objective: To assess safety, tolerability and persistence of effect of valbenazine in subjects with schizophrenia or… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)